(GMED) Globus Medical - Overview
Stock: Spine Implants, Orthopedic Trauma, Joint Replacements, Robotic Navigation
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 33.5% |
| Relative Tail Risk | -15.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -20.91 |
| Character TTM | |
|---|---|
| Beta | 1.026 |
| Beta Downside | 0.866 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.40% |
| CAGR/Max DD | 0.30 |
Description: GMED Globus Medical January 07, 2026
Globus Medical (GMED) designs, manufactures, and sells a broad portfolio of musculoskeletal devices-including spine fusion and motion-preservation implants, orthopedic trauma fixation, hip/knee arthroplasty components, and neuromonitoring services-plus advanced imaging, navigation, and robotic platforms such as ExcelsiusGPS and ExcelsiusFlex that support minimally invasive and robotic-assisted surgeries.
In FY 2023 the company reported revenue of approximately $1.1 billion, up roughly 10 % year-over-year, with operating margin expanding to 7.5 % as higher-margin robotics and software sales grew faster than traditional implant lines. R&D intensity remained around 12 % of revenue, reflecting continued investment in next-generation navigation and biologic technologies.
Key macro drivers for Globus include the aging U.S. population (the 65+ cohort is projected to reach 21 % of the population by 2030), rising prevalence of degenerative spine conditions, and a gradual shift toward value-based reimbursement that favors technologies promising reduced hospital stays and lower complication rates-attributes central to the company’s robotic and navigation solutions.
For a deeper quantitative assessment, you may find the ValueRay platform’s analyst tools useful.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 423.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.60 > 1.0 |
| NWC/Revenue: 52.65% < 20% (prev 49.97%; Δ 2.69% < -1%) |
| CFO/TA 0.14 > 3% & CFO 715.2m > Net Income 423.8m |
| Net Debt (-252.4m) to EBITDA (718.0m): -0.35 < 3 |
| Current Ratio: 4.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.4m) vs 12m ago -1.93% < -2% |
| Gross Margin: 64.26% > 18% (prev 0.58%; Δ 6368 % > 0.5%) |
| Asset Turnover: 54.41% > 50% (prev 48.73%; Δ 5.67% > 0%) |
| Interest Coverage Ratio: 149.1 > 6 (EBITDA TTM 718.0m / Interest Expense TTM 2.96m) |
Altman Z'' 5.25
| A: 0.29 (Total Current Assets 1.92b - Total Current Liabilities 466.0m) / Total Assets 5.10b |
| B: 0.25 (Retained Earnings 1.29b / Total Assets 5.10b) |
| C: 0.09 (EBIT TTM 441.9m / Avg Total Assets 5.09b) |
| D: 1.87 (Book Value of Equity 1.30b / Total Liabilities 696.8m) |
| Altman-Z'' Score: 5.25 = AAA |
Beneish M -3.03
| DSRI: 1.04 (Receivables 688.1m/593.2m, Revenue 2.77b/2.48b) |
| GMI: 0.90 (GM 64.26% / 58.14%) |
| AQI: 1.05 (AQ_t 0.50 / AQ_t-1 0.47) |
| SGI: 1.12 (Revenue 2.77b / 2.48b) |
| TATA: -0.06 (NI 423.8m - CFO 715.2m) / TA 5.10b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of GMED shares?
Over the past week, the price has changed by -3.16%, over one month by -5.87%, over three months by +42.29% and over the past year by -0.16%.
Is GMED a buy, sell or hold?
- StrongBuy: 4
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GMED price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 106.7 | 21.5% |
| Analysts Target Price | 106.7 | 21.5% |
| ValueRay Target Price | 87.5 | -0.3% |
GMED Fundamental Data Overview January 31, 2026
P/E Forward = 20.7469
P/S = 4.3992
P/B = 2.745
P/EG = 1.7253
Revenue TTM = 2.77b USD
EBIT TTM = 441.9m USD
EBITDA TTM = 718.0m USD
Long Term Debt = 119.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.4m USD (from shortTermDebt, last quarter)
Debt = 119.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -252.4m USD (from netDebt column, last quarter)
Enterprise Value = 11.91b USD (12.18b + Debt 119.3m - CCE 390.5m)
Interest Coverage Ratio = 149.1 (Ebit TTM 441.9m / Interest Expense TTM 2.96m)
EV/FCF = 20.55x (Enterprise Value 11.91b / FCF TTM 579.6m)
FCF Yield = 4.87% (FCF TTM 579.6m / Enterprise Value 11.91b)
FCF Margin = 20.93% (FCF TTM 579.6m / Revenue TTM 2.77b)
Net Margin = 15.30% (Net Income TTM 423.8m / Revenue TTM 2.77b)
Gross Margin = 64.26% ((Revenue TTM 2.77b - Cost of Revenue TTM 990.0m) / Revenue TTM)
Gross Margin QoQ = 63.28% (prev 66.62%)
Tobins Q-Ratio = 2.34 (Enterprise Value 11.91b / Total Assets 5.10b)
Interest Expense / Debt = 1.22% (Interest Expense 1.46m / Debt 119.3m)
Taxrate = 17.38% (25.0m / 144.0m)
NOPAT = 365.1m (EBIT 441.9m * (1 - 17.38%))
Current Ratio = 4.13 (Total Current Assets 1.92b / Total Current Liabilities 466.0m)
Debt / Equity = 0.03 (Debt 119.3m / totalStockholderEquity, last quarter 4.40b)
Debt / EBITDA = -0.35 (Net Debt -252.4m / EBITDA 718.0m)
Debt / FCF = -0.44 (Net Debt -252.4m / FCF TTM 579.6m)
Total Stockholder Equity = 4.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.32% (Net Income 423.8m / Total Assets 5.10b)
RoE = 9.99% (Net Income TTM 423.8m / Total Stockholder Equity 4.24b)
RoCE = 10.14% (EBIT 441.9m / Capital Employed (Equity 4.24b + L.T.Debt 119.3m))
RoIC = 8.39% (NOPAT 365.1m / Invested Capital 4.35b)
WACC = 9.62% (E(12.18b)/V(12.30b) * Re(9.70%) + D(119.3m)/V(12.30b) * Rd(1.22%) * (1-Tc(0.17)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.31%
[DCF Debug] Terminal Value 76.20% ; FCFF base≈465.3m ; Y1≈573.9m ; Y5≈977.5m
Fair Price DCF = 113.8 (EV 12.42b - Net Debt -252.4m = Equity 12.67b / Shares 111.4m; r=9.62% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 90.54 | EPS CAGR: 26.41% | SUE: 4.0 | # QB: 2
Revenue Correlation: 94.03 | Revenue CAGR: 34.94% | SUE: 0.81 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.91 | Chg30d=+0.017 | Revisions Net=+4 | Analysts=12
EPS next Year (2026-12-31): EPS=4.21 | Chg30d=+0.094 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+8.5%